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Abstract
Introduction: Almost from the beginning of the HIV epidemic in 1981, an association with tuberculosis (TB) was recognized. This
association between HIV and TB co-infection has been particularly evident amongst prisoners. However, despite this, few studies
of TB in prisons have stratified results by HIV status. Given the high prevalence of HIV-positive persons and TB-infected persons
in prisons and the documented risk of TB in those infected with HIV, it is of interest to determine how co-infection varies
amongst prison populations worldwide. For this reason we have undertaken a systematic review of studies of co-infected
prisoners to determine the incidence and/or prevalence of HIV/TB co-infection in prisons, as well as outcomes in this group,
measured as treatment success or death.
Methods: A literature search was undertaken using the online databases PubMed, Embase, IBSS, Scopus, Web of Science, Global
Health and CINAHL Plus. No restrictions were set on language or publication date for article retrieval, with articles included if
indexed up to 18 October 2015. A total of 1975 non-duplicate papers were identified. For treatment and outcome data all
eligible papers were appraised for inclusion; for incidence/prevalence estimates papers published prior to 2000 were excluded
from full text review. After full text appraisal, 46 papers were selected for inclusion in the review, 41 for incidence/prevalence
estimates and nine for outcomes data, with four papers providing evidence for both outcomes and prevalence/incidence.
Results: Very few studies estimated the incidence of TB in HIV positive prisoners, with most simply reporting prevalence of
co-infection. Co-infection is rarely explicitly measured, with studies simply reporting HIV status in prisoners with TB, or a cross-
sectional survey of TB prevalence amongst prisoners with HIV. Estimates of co-infection prevalence ranged from 2.4 to 73.1%
and relative risks for one, given the other, ranged from 2.0 to 10.75, although some studies reported no significant association
between HIV and TB. Few studies provided a comparison with the risk of co-infection in the general population.
Conclusions: Prisoners infected with HIV are at high risk of developing TB. However, the magnitude of risk varies between
different prisons and countries. There is little evidence on treatment outcomes in co-infected prisoners, and the existing
evidence is conflicting in regards to HIV status influence on prisoner treatment outcomes.
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Introduction
Almost from the beginning of the AIDS epidemic in 1981, an
association with tuberculosis (TB) was recognized. This
relationship is attributed both to the suppression of host
immune systems by human immunodeficiency virus (HIV) [1]
as well as environmental risk factors shared by the two
diseases [2]. People infected with HIV are 20 to 30 times
more likely to develop active TB than HIV-negative persons,
with an estimated one in three deaths among HIV-positive
persons due to TB in 2014 [3]. Although deaths from TB in
those living with HIV have fallen throughout the last decade,
360,000 deaths were attributed to co-infection in 2013 [4].
This association between HIV and TB co-infection has been
particularly evident amongst prisoners. Between 1976 and
1986 there was a fivefold increase in the incidence of TB
among inmates in the New York prison system, attributed in
part to infection with HIV [5]. Studies in other high-risk
populations such as intravenous drug users added to
evidence linking the two conditions [6], as did a 1990 study
of the prison population in Maryland that documented an
increased risk of infection with TB among prisoners who were
HIV positive. This increased risk fell just short of significance,
but this study may have lacked adequate power to detect a
difference [7].
There are several reasons for this association. First,
immunosuppression from HIV infection both predisposes
individuals to TB reactivation [8,9] and increases the risk of
progression from infection to disease [8,10]. Second, there is
some limited evidence from the USA that prisoners with a
history of TB may be more likely to engage in behaviours that
place them at a high risk of contracting HIV [11]. Third, the
two infections share a number of socio-demographic and
behavioural risk factors with each other and with the
probability of incarceration, such as injecting drug use [2].
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Fourth, conditions in prisons, such as poor ventilation and
overcrowding, increase the risk of transmission of TB. Fifth,
racial and ethnic groups that tend to experience proportio-
nately higher TB rates, such as blacks and Hispanics in the
USA, are often vastly over-represented, by up to 30 to 40
times [12], within prison populations [1315]. Yet, despite
the coalescence of all of these factors, knowledge of the
epidemiology of HIV/TB co-infection among those who are
incarcerated remains fragmentary.
There is already a large body of empirical evidence showing
that history of imprisonment is an important risk factor for
TB among those with AIDS [16,17] and those who engage in
high-risk behaviours for HIV infection [18]. However, co-
infection with HIV and TB among prisoners poses risks not
only to the prisoners themselves, but also to prison staff
[19,20] and contacts following release.
Risks associated with imprisonment extend beyond the
prisonwalls. Numerous studies have documented TB increases
in the broader population that can be attributed, at least
in part, to contacts with prison populations [2123]. More
recently, studies using genetic epidemiology have provided
important new insights into the role that prisons play in
community outbreaks of TB [24,25].
In part, this is because prisons act as incubators of TB [26].
Research in Eastern Europe and the former Soviet Union has
documented a close association between rates of incarcera-
tion and of both TB and multidrug resistant TB (MDR-TB), an
association exacerbated by a high prevalence of HIV [27]. The
aforementioned Russian study [25] found that TB spoligo-
types (a means of genotyping Mycobacterium tuberculosis
based on patterns of repeat units in DNA) were much less
heterogeneous amongst prisoners than the general popula-
tion, homeless or HIV-infected groups outside prison,
suggesting that TB infection is transmitted especially easily
amongst this confined group. Research in 1999 documented
cases of HIV-positive prisoners co-infected with more than
one M. tuberculosis strain [28].
Imprisonment also offers increased potential for TB out-
breaks to run rife amongst closely confined inhabitants and
prison staff, with numerous TB outbreaks having been
recorded amongst correctional facilities in the USA. In 1991 a
New York State correctional facility experienced a MDR-TB
outbreak from January to November 1991. Eight persons were
identified as havingMDR-TB, seven of whomwereHIV-positive
inmates and one a correctional facility worker, immunocom-
promised as a result of recent chemotherapy [29]. In South
Carolina (1999 to 2000) contact tracing of 323 prisoners
housed in the same dormitory as a TB index case, found 31 HIV-
positive inmates infected with TB, alongside a medical student
who examined the source case [30]. Meanwhile, between
1995 and 1996, TB outbreaks occurred amongst HIV housing
units in two separate Californian correctional facilities. In
prison A, a 500-person HIV housing unit, 14 inmates and the
wife of the index case were diagnosed with drug-susceptible
TB. In prison B, a 180-person HIV housing unit, an index case
resulted in 15 further cases of TB amongst inmates [31].
Given the high prevalence of HIV-positive persons and TB
infections in prisons [3234] and the documented risk of TB
in those infected with HIV, it is of interest to determine how
co-infection varies amongst prison populations worldwide.
In 2005 it was estimated that around one-third of co-infected
persons in Central Asia were found in penitentiaries [35].
However, definitive estimates of the prevalence and incidence
of co-infection in prisoners worldwide remains sparse, with
evidence suggesting that prisons often fail to implement
simple case-finding and screening procedures for infectious
disease [36]. For this reason we have undertaken a systematic
review of studies of co-infected prisoners, to determine the
incidence and/or prevalence of HIV/TB co-infection in prisons,
as well as outcomes in this group, measured as treatment
success or death. In this review, the terms prisoners and
inmates are used interchangeably and refer to both convicted
and pretrial (on remand) persons held in prisons, jails,
detention and other penal institutions.
Methods
A literature search was undertaken the online databases
PubMed, Embase, IBSS, Scopus,Web of Science, Global Health
(GH) and CINAHL Plus. No restrictions were set on language or
publication date, with articles included if indexed up to 18
October 2015. Medical subject and text word searches were
combined for terms relating to HIV/AIDS, TB, prisoner/prisons
and detention centres. Scopus searches were performed on
title and abstract for all terms, IBSS searches on keywords and
Web of Science searches as topics. The full search strategy
including all terms used is in Appendix.
This resulted in 3791 papers, and 2016 remained after
duplicates were removed by EndNote. All further library
management was undertaken using EndNote software.
Further duplicates were found when reviewing paper titles
and abstracts. These were manually removed, leaving 1975
papers. Titles and abstracts from these papers were reviewed
by two independent reviewers and were selected for further
appraisal according to the following criteria for inclusion: data
must be from empirical research; data must relate to either
incidence and prevalence of co-infection or outcomes of co-
infection; diagnostic methods employed in HIV and TB
detection must be specified, including HIV antibodies and TB
skin testing (TST) or direct microscopy but not x-ray alone;
research must be undertaken in a prison, jail, pretrial
detention centre or compulsory drug detention centre; data
must be available on the population denominator; and
information must be available on the timing of the study.
Case definition for TB can include latent TB infection (LTBI) and
active TB.
After papers that failed to meet inclusion criteria were
removed, 175 papers remained for full appraisal and the full
text was retrieved. After the full text appraisal, 46 papers
were selected for inclusion in the review, 41 for incidence
and prevalence estimates and nine for outcomes data, with
four in both categories. For full details of paper selection, see
Figures 1 and 2.
Results
Table 1 presents illustrative examples of global research on
TB/HIV co-infection. These studies provide further evidence that
prisoners infected with HIV are at high risk of developing TB.
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However, the magnitude of risk varies between different
prisons and countries.
Few studies reported the incidence of TB amongst HIV
positive inmates[15,55,56,65], with most simply reporting
results from cross-sectional surveys of TB/HIV prevalence or
assessing HIV status amongst those that develop TB, as
opposed to observing the incidence of TB amongst prisoners
of known HIV status. Of the four papers that did provide
measures of incidence, three found incidence of TB greater
amongst those who were HIV positive [15,56,65], whilst one
did not provide a comparison between HIV-negative and -
positive prisoners [55]. This lack of reported incidence
measures may be reflective of the challenges of calculating
these rates in a dynamic, transient prison population, such as
issues with accurate calculation of person time at risk, and
exclusion of prevalent TB cases, which may or may not be
apparent on entry [77].
Estimates of co-infection prevalence, as mentioned pre-
viously, tended to favour measuring HIV prevalence amongst
TB cases, although some studies measured prevalence of TB in
HIV-positive prisoners. Amongst TB cases, prevalence of HIV
positivity varied from 0.1% [47] to 73.1% [49]. There were few
clear geographical patterns within the results; studies per-
formed in African countries often reported co-infection
prevalence over 50% in TB cases [49,60,61,68]. As with
measures of incidence, this wide variation in prevalence
estimatesmay be in part due to the settings and characteristics
of the prisoners themselves but also in part to methodological
differences in calculation of prevalence.
Measures of association between TB and HIV positivity
were variable amongst those studies that reported it, with
some finding no significant association [40,58,60,65,73,75]
whilst others reported highly significant associations between
the two infections, with relative risks of co-infection ranging
from 2.0 to 10.75 [51,58].
There was a high risk of bias in many of the studies included
(Table A1), most often because studies were performed in
those with TB or HIV, as opposed to the entire prison
population. Few studies explicitly set out to measure co-
infection, often including HIV positivity in a list of character-
istics common to patients with TB. Even in studies that did not
specify whether an infected group was targeted, most often a
subset of the prison population was used, such as those with
respiratory symptoms. Amongst the studies case definitions
varied. In total, two examined LTBI diagnoses only, six at both
active TB and LTBI and 35 at active TB only.The bias inherent in
many of these studies means it is hard to draw any definitive
conclusions as to the size of the association or increased risk
between TB and HIV in prisoners. For this reason a formal
meta-analysis was not undertaken on the retrieved results,
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Figure 1. PRISMA flow diagram for articles on incidence and/or prevalence of HIV/TB co-infection in prisoners.
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nor simple summary measures produced, due to the con-
siderable heterogeneity between study methods and results
as demonstrated in Table A2.
Only six of the studies retrieved [2,50,53,62,69,70] pro-
vided any comparison of a prisoner’s risk of co-infection to
that of the general population. All of these studies found the
risk or prevalence of co-infection to be greater among prison
residents than that of the general community. However,
given the small numbers of studies reporting these compara-
tive data, it is hard to ascertain a definitive value of increased
risk. Therefore, we must simply conclude that the risk of
developing TB amongst HIV-positive inmates is high and
appears higher than for those outside of prison.
Few studies retrieved were recorded as performed in jails
(used to hold individuals awaiting trial or sentencing)
[39,40,47,73,74], meaning most of the conclusions drawn
were based on those resident in prisons, who are likely to be
less transient than jail or remand populations. One jail study
found HIV positivity predictive of TB (odds ratio (OR) 3.07;
pB0.01) [73], whilst another found very few cases of co-
infection (n2/2103) [47], making it hard to draw conclusions
on co-infection risk in jail. Those in jails may potentially be
more likely to represent people who are incarcerated with TB,
as short length of staymay preclude TB development; however
this association is unproven. In addition, short-stay prisoners
may represent a population with high rates of recidivism [78],
therefore returning as a prevalent case if TB treatment com-
pletion was complicated by the short stay nature of jails [73].
While noting the caveats concerning TST, research suggests
that prisoners are no more likely to be infected with TB [79]
but are more likely to develop active disease [44,56,60,73]
than people residing outside of prison. Indeed, one study
found no association between HIV positivity in prisoners and
LTBI [40]. One of the few studies among female prisoners,
from Brazil, found that while the TB infection prevalence was
similar among women with or without HIV infection, with a
purified protein derivative test conversion rate of approxi-
mately 30% in both, the incidence of TB was 9.9 per 100
person-years among those who were HIV positive compared
with 0.7 per 100 person-years in those who were negative
[80]. This same study found that the development of TB was
most likely within the first 12 months of incarceration, as was
also the case in a Texan prison [15].
Some studies looking at activation of disease have found an
association between TB and CD4 counts below 200 cells/mm3
[81,82], whilst others suggest a significantly increased risk
below 350 cells/mm3, with risk rapidly increasing as CD4 count
decreases [16]. Therefore, differing rates of active disease
co-infection between settings may in part be explained by the
stage of AIDS in HIV-positive prisoners. Receipt of antiretroviral
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Figure 2. PRISMA flow diagram for articles on outcomes of HIV/TB co-infection in prisoners.
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therapy (ART) by prisoners could also impact on the observed
heterogeneity in co-infection rates, with those receiving
therapy less likely to succumb to opportunistic infections.
Prevention and treatment
Low rates of TB treatment completion amongst the prison
population in general are well documented, and the reasons
are multifactorial. Many low- and middle-income countries
[83] have severely limited prison health facilities, and prison-
ers with symptoms suggestive of TB may go undiagnosed. In
addition, access to appropriate chemoprophylaxis in prisons
can be problematic due to reasons such as affordability,
circulation of suboptimal drugs and the low priority given to
prison healthcare by policymakers [84,85]. In addition, the
movement of prisoners, both within and out of the prison
system, exacerbates the rate of treatment default.
Evidence on the quality and effectiveness of treatment in
those with co-infection is fragmentary. However, the available
evidence indicates that, even in general populations, there
are substantial geographical variations. For example, patients
in Eastern Europe are significantly less likely to receive
adequate treatment for both conditions than those in other
parts of Europe or Latin America [86]. For prisoners with co-
infection, treatment completion is complicated by both the
nature of this transient population and the complex drug
regimes required for co-infected patients, sometimes result-
ing in adverse drug-drug interactions [15,87]. HIV positivity is
not generally associated with TB treatment adherence [88].
However, one US study of prisoners with latent TB found that
they were less likely to complete treatment if they were HIV
positive, with defaults attributed to movements within the
correctional system, refusal of treatment and adverse drug
effects [74]. The results for treatment outcomes have been
summarized in Table 2.
There have been a few studies of TB outbreaks among
HIV-positive prisoners. One review concluded that, although
consideration must be given to drug-drug interactions invol-
ving ARTand anti-TB medication, shorter drug regimes remain
preferable, due to the transitory nature of the prison
population [91].
The available evidence provides several other important
findings. First, in HIV-positive prisoners found to have evidence
of infection by TST, latent TB infection treatment can reduce
the incidence of TB [65]. Second, where effective treatment is
provided, outcomes of TB infection among those infected
with HIV, at least where immunosuppression is mild or ART is
also provided, are as good as in HIV-negative prisoners [92],
consistent with other evidence that treatment for drug-
sensitive TB is effective in the early stages of immunodefi-
ciency [93]. Third, in the presence of sensitivity testing and
continuity of treatment, those with HIV infection are at no
greater risk of developing MDR-TB, beyond their risk for TB in
general [94,95], and, in one Russian study, prisoners with co-
infection were significantly less likely to develop resistance,
although the explanation was unclear [96].
Isolation of infectious prisoners to prevent further spread
is not consistently documented. Moreover, many of those
isolated may not be receiving treatment, conditions are
frequently appalling and these facilities may be used to holdTa
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uninfected juveniles thought to be at risk from older, violent
prisoners elsewhere in the prison [97]. As mentioned pre-
viously, the segregation of prisoners into HIV-infected units
provides an ideal opportunity for TB to spread rapidly
amongst this vulnerable population [31]. Even in high-income
countries there may be problems. For example, in US prisons,
Hispanics are systematically less likely to be tested for HIV
and TB than white prisoners [98].
Discussion
This review provides evidence that individuals infected with
HIV who reside in a prison setting are at high risk of developing
active TB, with this risk varying vastly by factors such as prison
location and prison population density. This is consistent with
literature reporting higher rates of TB and HIV individually,
amongst prison populations worldwide, as noted in a recent
paper from which this systematic review arose [99]. It has
summarized an extensive body of literature on its determi-
nants and the responses to it. It is clear that, if services
appropriate to the scale of the problem are to be developed,
further research is needed to accurately quantify the burden of
co-infection in prison populations today and the differences
between and within countries, as well as the outcomes
prisoners can expect during and after treatment. In this review
most of the studies citing numbers of co-infected prisoners
did not have this as their primary objective, more often
recording HIV positivity as one of numerous variables in
patients with TB, so that these estimates of prevalence/
incidence are merely a by-product of different research
objectives. As noted by Rieder et al., new prison entrants
may be more likely to participate in screening processes,
meaning that prevalence estimates may be higher if made at a
time when the proportion of new entrants was high.
Prevalence can also vary according to the case definition
used for inclusion [77].With most studies reporting only cross-
sectional results, it remains hard to disentangle whether
imprisonment increases the risk of developing TB over the
course of imprisonment, whether thosewith TB aremore likely
to be imprisoned and found to be HIV positive during prison-
based screening, or whether in fact high prevalence estimates
result from a combination of both these factors[A8]. Overall, it
is apparent that there is a need for accurate quantification
of the burden of co-infection in high-risk prison settings.
Considerationmust be given to the funding and administration
in resource-poor settings. In England, which maintains a
comprehensive infectious disease surveillance programme
based in Public Health England, the national public health
agency, there are problems in ascertaining rates of co-
infection. Although [A9]TB is a notifiable disease and autho-
rities are required to report it upon detection, the same is not
true of HIV status, despite the associated benefits for public
health, such as contact tracing and treatment [100]. Without
robust surveillance systems to confirm numbers of co-infected
prisoners, it will be nearly impossible to monitor and appraise
the effectiveness of interventions to reduce the rates of co-
infection.
Studies of treatment outcomes in those co-infected were
even more limited, with results conflicting as to the impact of
HIV positivity on treatment outcomes. Prisoners were oftenTa
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lost to follow-up post-release, thereby reinforcing the need
for a robust continuum of care to ensure treatment comple-
tion as well as monitor and evaluate treatment effectiveness.
Further research is needed to determine optimum treatment
regimes, delivery models and expected outcomes in this
population.
This reflects the relative paucity of studies on TB in prisons
[101], few of which have stratified results by HIV status [102].
It also reflects the scarcity of studies of HIV/TB co-infection
in general. A recent international systematic review of co-
infection studies, excluding China, found 47 studies, and just
one on prisoners [103]. However, this shed light on several
important issues. First, those studies combining chest radio-
graphy with serology produced higher estimates, consistent
with what is known about the lower sensitivity of sputum
culture and the problems of interpreting TST in individuals
who are immunosuppressed and therefore less likely to react
[52,64,104,105]. Second, it confirmed an earlier study show-
ing that co-infection was more likely in those communities
where the prevalence of HIV was highest [106]. However, the
use of different methodology precluded comparison.
Heterogeneity observed in study results is likely due in
part to study design but also to the differences between
prisons themselves. Prisons are diverse, both in terms of the
accommodation style and the numbers and demographic
characteristics of their inhabitants. Prisons may be mixed or
single sex, with some previously segregating HIV-positive
inmates into separate housing facilities, although this is now
rare [31]. Rooms range fromwell-equipped single cells to cold,
dark, damp concrete boxes accommodating large numbers of
prisoners, with one study from Ethiopia reporting an average
number of 333 prisoners per cell [49]. As one UN inspector
visiting a predetention centre in Russia noted, it would need
the literary skills of Dante or the artistic skills of Hieronymus
Bosch, to describe fully the horrors with which she was
confronted [107]. Recent data showed that, in 40% of 193
countries, prison occupancy was over 100% of stated prison
occupancy capacity; more than half of overcrowded prisons
had occupancy rates between 150 and 200% of capacity and
15 were above 200% of capacity. Some approached 400%
[108,109]. A study that modelled the transmission dynamics of
outbreaks of TB originating in institutions such as prisons and
mines concluded that the most important factors were the
size of the population within the institutions and movement
between them and the community [110]. Therefore, it is
almost inevitable that the scale of HIV/TB co-infection will vary
between countries and, within them, between prison settings,
regardless of study methodology and associated bias.
A recurring theme in the quest to improve treatment
outcomes was loss to follow-up of patients released from
prisons [61,74,89]. This topic has been the subject of
numerous studies, particularly in regard to continuing HIV
therapy [111,112]. A recent systematic review found improve-
ments along the pathway of care for HIV during incarceration,
often beyond what was achieved in the general population,
but problems rapidly arose as soon as subjects were
released from jail [111]. Recommendations to address this
problem are complex [112,113], acknowledging the compet-
ing demands in prisoners’ lives once they are released back
into the community. As re-incarceration has been known to
reach up to 76% within five years of release [113], inadequate
treatment of LTBI [74], which later manifests as active TB in
patients with HIV, may result in the reintroduction of TB both
into the community and back into the prison system. In
addition, loss to follow-up and therefore non-compliance with
the full TB treatment regime contributes to the development
of drug-resistant strains of TB [114,115]. Particular attention
must therefore be paid to developing models of treatment
continuum that are acceptable to prisoners post-release.
This systematic review is subject to certain limitations.
Although there was no restriction on publication date for
paper retrieval, we did not include data on co-infection
incidence and/or prevalence from papers published prior to
1999, as their relevance to the current situation is dubious
given the changing epidemiology of TB and HIV since this
period. Prevalence or numbers of co-infected prisoners
documented only in conference abstracts were not presented,
as it is unknown whether this information was subjected to
critical peer review, and many of these abstracts failed to
document clearly the methods of ascertaining infection status.
Several high quality studies documented rates of HIV, TB and
other infections amongst a specific prison population but
failed to give any data on numbers with co-infection. It is
plausible that direct contact with these authors may have
yielded further information. However, there may be doubt
about whether the results provided would be accurate
if co-infection was not specifically recorded and reported
during the original study.Manyof the papers presented did not
set out purposefully to record levels of co-infection, but
instead measured numbers of HIV-positive people amongst TB
cases, or vice versa, meaning prevalence estimates within the
entire prison population could not be calculated. International
comparisonsmust also be undertakenwith care because of the
very different nature of prisons, the analyses undertaken in
these studies and the methods used to identify TB infection.
Moreover, rates of co-infection will be influenced by what is
happening in the general population, which also varies greatly.
Conclusions
If the tide of HIV/TB co-infection in prisons is to be stemmed,
there is a clear need to develop and implement specific,
coordinated policies for active case-finding and treatment of
co-infected prisoners, for both those in prison settings and
those transitioning back into the community. This will bring
benefits to the individuals concerned but also reduce the
reservoir of disease, both within the prison population and
the community at large. The difference in the care provided to
prisoners and the general population, as well as the priority it
achieves on the policy agenda, has long been recognized.
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Appendix
Literature search terms and methodology
The following medical subject (MeSH) terms were included as exploded terms for HIV/AIDS if present in the database: Human
immunodeficiency virus (Embase, GH, CINAHL), human immunodeficiency virus infection (Embase), acquired immune deficiency
syndrome (Embase, GH), AIDS related complex (Embase), HIV (PubMed), HIV infections (PubMed, GH, CINAHL), Acquired
immunodeficiency syndrome (PubMed), Acquired immunodeficiency syndrome virus (PubMed), AIDS related complex
(PubMed), AIDS related opportunistic infections (PubMed, CINAHL), HIV seropositivity (PubMed, CINAHL), HIV seroprevalence
(PubMed), HIV 1 (PubMed, CINAHL), HIV 2 (PubMed), AIDS serodiagnosis (CINAHL). These terms were also combined with text
word searches for the following: HIV infect* OR HIV OR HIV OR HIV-1* OR HIV-2* OR human immun#deficiency virus OR human
immun#-deficiency virus OR acquired immun#deficiency syndrome OR acquired immun#-deficiency syndrome OR AIDS OR
AIDS related complex OR AIDS related opportunistic infection* OR HIV seropositivity OR HIV seroprevalence OR HIV 1* OR HIV
2* OR HIV/AIDS OR HIV-infected. Searches in Scopus were performed on title and abstract for all terms, and as topics in Web of
Science. IBSS searched the keywords for HIV and AIDS.
The following MeSH terms were included as exploded terms for tuberculosis if present in the database: Tuberculosis (Embase,
PubMed, GH, CINAHL), Multidrug resistant tuberculosis (Embase), Tuberculosis, multidrug-resistant (PubMed, CINAHL), Latent
tuberculosis (Embase), Infections Latent tuberculosis (PubMed), Mycobacterium tuberculosis (Embase, PubMed, GH, CINAHL),
Drug resistant tuberculosis (Embase), Extensively drug resistant tuberculosis (Embase, PubMed). These were also combined with
text word searches for the following terms: tuberculosis or TB or Mycobacterium tuberculosis or multi-drug resistant tuber-
culosis or multi-drug resistant TB or multiple drug resistant tuberculosis or multiple drug resistant TB or multidrug resistant
tuberculosis or multidrug resistant TB or MDR tuberculosis or MDR TB or XDR TB or XDR tuberculosis or extensiv* drug resistant
tuberculosis or extensiv* drug resistant TB. Searches in Scopus were performed on title and abstract for all terms, and as topics
in Web of Science. IBSS searched the keyword tuberculosis.
The following MeSH terms were included as exploded terms for prisoners if present in the database: prison (Embase), prisons
(PubMed), prisoner (Embase), prisoners (PubMed, GH, CINAHL), offender (Embase), correctional institutions (GH), correctional
facilities (CINAHL). These were also combined with text word searches for the following: prison* OR inmate OR inmates OR jail
OR gaol* OR correction* facilit* OR penitentiar* OR prison officer* OR penal institut* OR detention camp* OR custod* OR
concentration camp* OR incarcerate* OR imprison* OR correctional setting* OR detain* OR detention* OR correctional centre.
Searches in Scopus were performed on title and abstract for all terms, and as topics in Web of Science. IBSS searched the
keyword prison*.
The following MeSH term was included as an exploded term for detention centres if present in the database: detention camp
(Embase). This was also combined with text word searches for the following: compulsory drug detention OR compulsory drug
detention OR compulsory drug treatment OR compulsory rehabil* OR correction* center* OR correction* facilit* OR re-
education through labour OR laojiaosuo OR long-term detention OR labour camp*. Searches in Scopus were performed on title
and abstract for all terms, and as topics in Web of Science.
The prison and detention centre categories were combined with OR, following which all categories (HIV/AIDS, tuberculosis,
prison/detention) were combined with AND, in all searches.
1800 of the 1975 papers reviewed failed to meet at least one of the inclusion criteria, most often due to a lack of specification
and/or unacceptable diagnostic methods, or information only on co-infection policy, and were discarded. Therefore 175 papers
remained for full appraisal for inclusion and the full text was retrieved.
For information on incidence and/or prevalence of co-infection, papers were discarded if published prior to 2000 or were
published as a conference abstract only, due to the very different epidemiology of co-infection prior to 2000 and the limited peer
review of conference abstracts. This excluded a further 48 papers, leaving 127/1975 papers. In addition, two papers could not be
retrieved and 84 papers were excluded on full text review, leaving 41 papers for inclusion in regards to incidence/prevalence of
co-infection (Figure 1). For information on prisoner co-infection outcomes, papers were not excluded solely on publication date.
Of the 175 full text papers retrieved, 166 were excluded after a full text screen, leaving nine articles for inclusion in the review
(Figure 2).
Thereafter 46/1975 papers were selected for inclusion in the review, 41 for incidence/prevalence estimates and nine for
outcomes data, with four in both categories.
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Table A1. Bias assessment of studies
Study
Diagnostic
method
Case
definition Sample
Prevalent
or incident Response bias
Co-infection
study
Loss to
follow-up
CDC 2003       
Aily 2013     ?  
Bosco de Oliveira 2004 ?    ?  
Estevan 2013       
Lemos 2009       
Sanchez 2005       
Valenca 2015       
Noeske 2006     ?  
Noeske 2011       
Rueda 2013       
Rueda 2012     ?  ?
Gomez 2015       
Moges 2012       
Alavi 2014 ?      
Amwayi 2010       
Margolis 2013       ?
Al-Darraji 2013       
Cerecer 2006     ?  ?
Hernandez-Leon 2012     ?  ?
Chigbu 2010   ?  ?  
Lawal 2009       
Drobniewski 2005       
Telisinghe 2014       
Davies 2012 ?      
Nyasulu 2015 ?    ?  
Mnisi 2013 ?      
De la Hoz 2001       ?
Fernandez-Martin 2000     ?  ?
Marco 2012     ?  ?
Martin 2001     ?  
Winetsky 2014     ?  ?
Rutta 2001       
Schwitters 2014 ?      
Dubrovina 2008       
Raykhert 2008 ?      
Ferenando 2014       
MMWR 2007 ?  ?  ?  ?
Kim 2005 ?      
Lobato 2003     ?  ?
Baillargeon 2002       
Henostroza 2013     ?  ?
Harris 2014       ?
Maggard 2015     ?  ?
 low risk of bias; ? unknown risk of bias;  high risk of bias. Diagnostic method: Risk of bias due to method used to confirm infection. Unknown
diagnostics were studies based on known TB/HIV cases with no diagnostic method listed, often retrospective studies of hospital case notes. Case
definition: Was a case definition clearly defined, for example active TB/LTBI/both? Sample: Was the sample representative of the prison as a
whole, that is not within a prison subgroup only but a statistically representative sample? Prevalent or incident: Was only prevalence assessed,
which may be open to bias, dependent on prison composition at this time point? Response bias: Was there any potential bias in those who
refused TB/HIV screening? Co-infection study: Did the study specifically aim to measure co-infection? Loss to follow-up: Were many prisoners
lost or results not read, for example from tuberculin skin test, due to prison turnover?
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